Blurbs

Maxim Group Remains a Buy on Inmune Bio (INMB)

Maxim Group analyst Jason McCarthy maintained a Buy rating on Inmune Bio (INMBResearch Report) yesterday and set a price target of $22.00. The company’s shares opened today at $7.74.

McCarthy covers the Healthcare sector, focusing on stocks such as Adial Pharmaceuticals, Lineage Cell Therapeutics, and Plus Therapeutics. According to TipRanks, McCarthy has an average return of -40.3% and a 12.87% success rate on recommended stocks.

Currently, the analyst consensus on Inmune Bio is a Moderate Buy with an average price target of $14.50.

See the top stocks recommended by analysts >>

The company has a one-year high of $17.59 and a one-year low of $4.63. Currently, Inmune Bio has an average volume of 50.78K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Inmune Bio, Inc. is a clinical stage biotechnology company, which develops immunotherapies that reprogram a patient’s innate immune system to allow the immune system to fight cancer. Its products include INKMUNE and INB03. The company was founded by Mark Lowdell in September 2015 and is headquartered in La Jolla, CA.

Read More on INMB:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More